Marco Ladetto (Alessandria) Umberto Vitolo (Candiolo -TO)
SESSION 1: LARGE B-CELL LYMPHOMA

A. Di Rocco, F. Zaja

DEBATE - Molecularly driven vs agnostic treatment strategies in first line DLBCL
G. Lenz vs M. Gomes da Silva
The evolving landscape in R/R DLBCL: bispecifics, ADC and novel engineered antibodies
M. Trneny
CNS prophylaxis: an old chap or a still valid option?
T. Calimeri
SESSION 2: HODGKIN LYMPHOMA AND T-CELL LYMPHOMA

L. Rigacci, C. Rusconi

DEBATE - Minimizing toxicity and preserving efficacy in early-stage Hodgkin lymphoma: the radiation oncology perspective
U. Ricardi
DEBATE - Minimizing toxicity and preserving efficacy in early-stage Hodgkin lymphoma: - the chemoimmunotherapy perspective
I. Aurer
DEBATE - Immunochemotherapy-based strategies for sparing toxicity and improving efficacy in advanced-stage Hodgkin lymphoma: Beacopp-based
P. Borchmann
How I treat high risk T-cell lymphomas
A. Chiappella
LECTURE I

U. Vitolo

The paradigm shift in the treatment of follicular lymphoma from chemoimmunotherapy to chemo-free approaches with bispecifics, novel engineered antibodies, and small molecules
G. Salles
SESSION 3: INDOLENT LYMPHOMA

A. Conconi, G. Gini

Biology of high-risk indolent lymphoma
J. Okosun
First line treatment in high-risk follicular lymphoma
S. Luminari
Waldenström macroglobulinemia: from chemoimmunotherapy to chemo-free approaches
C. Buske
SESSION 4: MANTLE CELL LYMPHOMA

M. Balzarotti, M. Martelli

How MRD detection is changing in the era of BTKi in MCL
C. Pott
The role of BTK inhibitors in first line MCL therapy
M. Jerkeman
Chemo-free approaches in relapsed/refractory mantle cell lymphoma
C. Visco
LECTURE 2

M. Ladetto

Novel frontiers with CAR-T treatment in B-cell malignancies
M.J. Kersten
SESSION 5: CHRONIC LYMPHOCYTIC LEUKEMIA

A. Cuneo, M. Massaia

Biology of high risk CLL and acquired resistance
D. Rossi
Role of combination treatment in first line
O. Al-Sawaf
How I treat BTKi failures
W. Jurczak
SESSION 6: MULTIPLE MYELOMA

S. Bringhen, B. Bruno

Static and dynamic prognostic factors in multiple myeloma: roles of disease biology and MRD
S. Oliva
DEBATE - CAR-T vs bispecific antibodies: real roles in real life - CAR-T
M. D’Agostino
DEBATE - CAR-T vs bispecific antibodies: real roles in real life - Bispecifics
K.A. Ramasamy
SESSION 7: MYELODISPLASTIC SYNDROME

D. Cilloni, G. Saglio

DEBATE - TP53-mutated MDS: is transplant the only way? Yes
D. Valcarcel
DEBATE - TP53-mutated MDS: is transplant the only way? No
D. Cilloni
Symptomatic anemia in MDS: when and how to treat
E. Crisà
SESSION 8: ACCESS DISPARITY TO NOVEL TREATMENTS AS A NOVEL “HIGH RISK”

R. Foà, G. Gaidano

Current situation and how to foster access in medium income countries
A. Perolla
The role of international societies in promoting worldwide access to modern diagnosis and treatment
G. Gaidano
SESSION 9: ACUTE LYMPHOBLASTIC LEUKEMIA

E. Audisio, D. Pietrasanta

Biology of high risk ALL
M. Brueggemann
The evolving strategies in the treatment of young adults and elderly patients with acute lymphoblastic leukemia
A. Rambaldi
Allogeneic transplant and CAR-T in adult ALL: which comes first?
N. Goekbuget
SESSION 10: ACUTE MYELOBLASTIC LEUKEMIA

G. . Saglio, A. Venditti

Biologic features of HR-AML
R. Palmieri
High risk AML: how to incorporate new drugs into the treatment of AML
P. Metha
Allogenic stem cell transplant in HR-AM
C.F. Craddock
Privacy Policy | Cookie Policy